MedTrace Logo

OE MRI to Predict Treatment Response After TACE in HCC Patients

NCT07617038 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-06-01

No results posted yet for this study

Summary

To predict response of HCC to TACE using dynamic oxygen-enhanced (dOE)-MRI for assessment of the level of tumor hypoxia before and after treatment.

Conditions

  • HCC - Hepatocellular Carcinoma
  • TACE
  • SIRT

Interventions

DIAGNOSTIC_TEST

MRI contrast-enhancing agents

MRI before and after treatment

Sponsors & Collaborators

  • Laboratory ISTCT UMR6030 CNRS of Caen (France)

    collaborator UNKNOWN

  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal

    collaborator OTHER

  • Université de Montréal

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-27
Primary Completion
2027-12-20
Completion
2029-12-20

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07617038 on ClinicalTrials.gov